Today's Daily Dose brings you news about the delay in filing of AVEO Pharma's NDA for FOTIVDA for renal cell cancer; Corcept's lower-than-expected fourth quarter revenue; Edwards LifeSciences' strong profitability and 10 percent sales growth in Q4; suspension of OPKO Health's Benign Prostatic Hyperplasia trial; and FDA approval of first generic of Glaxo's ADVAIR DISKUS.
from RTT - Biotech http://bit.ly/2SkUtaC
via IFTTT
No comments:
Post a Comment